Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.